Ryan C. Fields, MD

Articles by Ryan C. Fields, MD

ILI Provides Valuable Option for Inoperable Melanoma Metastases

March 4th 2014

As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.

Latest Updated Articles

ILI Provides Valuable Option for Inoperable Melanoma Metastases
Published: March 4th 2014 | Updated:

Ryan C. Fields, MD

Articles by Ryan C. Fields, MD

ILI Provides Valuable Option for Inoperable Melanoma Metastases

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma